| Identification | Back Directory | [Name]
Delgocitinib | [CAS]
1263774-59-9 | [Synonyms]
JTE052
JTE-052
LEO124249
LEO 124249
Delgocitinib
Delgocitinib(JTE-052)
Corectim（Delgocitinib）
1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (3S,4R)-
3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile | [Molecular Formula]
C16H18N6O | [MDL Number]
MFCD31630732 | [MOL File]
1263774-59-9.mol | [Molecular Weight]
310.35 |
| Chemical Properties | Back Directory | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:58.0(Max Conc. mg/mL);186.89(Max Conc. mM) | [form ]
Solid | [pka]
-0.65±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Characteristics]
Class: non-receptor tyrosine kinase
Treatment: atopic dermatitis (topical ointment)
Protein binding = 22–29% | [Definition]
ChEBI: Delgocitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory drug, an antipsoriatic and an antiseborrheic. It is a pyrrolopyrimidine, a tertiary amino compound, a nitrile, an azaspiro compound, a tertiary carboxamide and a N-acylazetidine. | [Clinical Use]
Delgocitinib is a pan-JAK inhibitor that inhibits all Janus Kinase (JAK) family members. Topical delgocitinib 0.5% ointment received its first approval in Japan in 2020 for treating adults with atopic dermatitis. The FDA has granted delgocitinib cream fast-track designation for chronic hand eczema.
| [storage]
Store at -20°C |
|
|